… quantification of lacidipine in human … for lacidipine and m/z 389.2 → 315.0 for IS, respectively.
Then, the established method was applied in a bioequivalence study comparing lacidipine …

… model for evaluating bioequivalence of oral lacidipine formulations in dogs. The dissolution
behaviors of three lacidipine formulations including one … Clinical pharmacology of lacidipine …

… Lacidipine, a calcium channel blocker, can protect gastric tissue from aspirin-induced …
analgesic, and gastric tissue effects of using lacidipine and aspirin in combination and separately. (…

… antihypertensive therapy with lacidipine and candesartan on … and angiotensin receptor
blocker (lacidipine 2 mg, 4 mg, and … antihypertensive therapy with lacidipine and candesartan, a …

… The present study is aimed to explore the effects of lacidipine … , tid) from days 1 to 7 and
alongside lacidipine (0.3, 1, and 3 mg/… subjected to nicotine-withdrawal and lacidipine (3 mg/kg) …

… in the formulation of lacidipine, a 100ml stock solution of lacidipine hydrochloride was
prepared. For the purpose of quantifying the intermediate in the lacidipine formulation, 4 ml of …

… lacidipine (LCD), L-type Ca 2+ -channel blocker, on reserpine-induced depression in mice.
Separate groups of mice (Swiss albino, 18–25 g) were administered lacidipine … that lacidipine …

… The medicine data based on available and currently known evidences in the field of clinical
pharmacology allow determination of the principles of selection and assessment of the use …

… cells treated with Lacidipine showed enhanced activity of caspase-3 in the luminal space.
Pharmacological inhibition of caspase activity abolished the Lacidipine-enhancing effect on …

… lacidipine-induced improvement in memory and redox balance in scopolamine-administered
mice. Lacidipine … These properties of lacidipine can mitigate the pathogenesis of AD-type …